DSIP and sleep: a fifty-year-old literature that never settled

DSIP stands for delta sleep-inducing peptide, and the name is the problem. It records what a Swiss group was looking for when they found the molecule, not anything the molecule has been shown to do. Fifty years of work has not settled the question the name asks, and that non-replication is the literature rather than a footnote to it.

That is worth saying before anything else, because the name does the arguing on its own.

Where it came from

The thread begins with cross-circulation experiments in rabbits in the 1960s, in which Marcel Monnier's group at Bern reported that blood drawn from an animal in an electrically induced sleep state altered the electroencephalogram of a second animal. A transferable factor was the hypothesis. Isolating it took another decade: Schoenenberger and Monnier characterised a nonapeptide from rabbit cerebral venous blood and published it in 1977 (PMID 265572).

The sequence is nine residues — WAGGDASGE — which is one of the few things about this compound that is checkable rather than contested. It is a small, acidic peptide with no unusual chemistry.

Two practical notes follow from that sequence. The single tryptophan at the first position is the only residue that absorbs usefully in the near ultraviolet, which is what an HPLC detector reads at 280 nm. And with four glycine or alanine residues and two acidic side chains, the peptide is small, polar and freely water-soluble. Nothing about handling it is difficult; the difficulty is entirely in interpreting the papers.

What the studies measured

Animal work measures sleep architecture directly, by electroencephalography: slow-wave and REM proportions, sleep latency, total sleep time. Those are recordings from an animal under anaesthesia-free electrode implantation, and they are the most objective endpoints in the whole file.

The human studies are the reason anyone has heard of the compound, and there are very few of them. Schneider-Helmert reported in the Lancet in 1981 on synthetic DSIP in insomnia (PMID 6112579) and followed it with a study of twenty-four-hour sleep-wake behaviour in severe chronic insomnia in 1987 (PMID 3622582). Bes and colleagues ran a double-blind study of DSIP on the sleep of chronic insomniac patients, published in 1992 (PMID 1299794). A separate thread examined chronic pain: Larbig and colleagues published a clinical pilot study in patients with pronounced pain episodes in 1984 (PMID 6548970).

Read the dates. Almost the entire human record sits between 1977 and 1992, in small samples, in journals of the period, with no programme connecting one study to the next. There is no modern randomised controlled trial, no registered clinical programme, and nothing resembling a replication attempt by an independent group with current methods.

What the reviews concluded is the honest summary. Graf's reviews of 1984 and 1986 (PMID 6145137, PMID 3550726) catalogued a long list of reported actions across sleep, thermoregulation, endocrine release and stress responses. Kovalzon and Strekalova, writing in the Journal of Neurochemistry in 2006, titled their review "a still unresolved riddle" (PMID 16539679). Thirty years on from the isolation, a review's title was a shrug. That is unusual, and it is the most useful single fact about this literature.

The receptor problem

No receptor for DSIP has been identified. Autoradiography on cultured rat brainstem neurones reported binding sites in the early 1980s (PMID 6688964), and transport work found a saturable mechanism at the blood-brain barrier of the vascularly perfused guinea pig brain (PMID 2547200) — but a binding site in a culture dish and a cloned, characterised receptor with a known signalling pathway are different things, and only the first exists here.

That gap explains a lot. A molecule with no identified target is hard to study systematically: there is no assay to screen against, no way to confirm that an observed effect is on-target, and no basis for predicting what a change in exposure should do. It also explains the breadth of the reported action list. When a compound is reported to affect sleep, temperature, pituitary hormones and pain in different laboratories, with no mechanism tying those together, the most economical reading is that some of those reports will not hold.

Where the evidence stops

It is old. The bulk of it predates current standards for trial registration, pre-specified endpoints and publication of negative results.

It is small. Participant counts are in the tens, not the hundreds.

It is unreplicated. This is the decisive one. A finding that two independent groups reproduce is an established finding; a finding that sits alone is a hypothesis with a citation.

It has no mechanism. No receptor, no characterised pathway.

It is approved nowhere. Not by Health Canada, not by the FDA, not by the EMA, for any indication, in any formulation. There is no licensed DSIP product anywhere in the world, and there never has been.

For the adjacent literature on circadian and pineal signalling, where the mechanistic groundwork is better developed, see Epithalon, melatonin and the pineal. For a peptide whose human work is more recent and better documented, see Selank and the stress response, and for another hypothalamic research tool with a live human physiology literature, Kisspeptin-10. Nothing here is medical, dosing, or therapeutic guidance.

What a researcher can actually control

Not an amount — no figure here converts from a 1980s study to anything else, and none is given. What is controllable is concentration, which is plain arithmetic: a 10 mg vial reconstituted with 2 mL of diluent gives 5 mg/mL, and the same vial with 5 mL gives 2 mg/mL. The reconstitution calculator on this site does that arithmetic, and bacteriostatic water is the diluent such work is normally prepared with.

DSIP is supplied here as DSIP. Janoshik-verified by HPLC with mass-spec identity confirmation; 100% synthetic. The measured purity for each lot is stated on its product page. For laboratory research use only.

Common questions

Does DSIP induce delta sleep? Unknown, and the name should not be read as an answer. A handful of small human studies from the 1980s and early 1990s examined the question, the reviews describe the results as unresolved, and no modern trial has revisited it.

Why is the literature so thin for a compound this old? Partly because the field moved — orexin, adenosine and melatonin signalling turned out to be more tractable, and funding followed them. Partly because no receptor was ever found, which left nothing to build a research programme around.

Is any of the human work usable? As history, yes. As evidence for anything, no: the studies are too small and too old to support a conclusion, and none has been replicated.

Is it legal to buy in Canada? It is sold here as a research chemical, for laboratory use only. It is not an approved drug in Canada and is not sold for human use.

Selected Research References

1. Schoenenberger GA, Monnier M. Characterization of a Delta-Electroencephalogram (-Sleep)-Inducing Peptide. Proceedings of the National Academy of Sciences. 1977;74(3):1282-1286. pubmed.ncbi.nlm.nih.gov/265572
2. Graf MV, Kastin AJ. Delta-Sleep-Inducing Peptide (DSIP): A Review. Neuroscience & Biobehavioral Reviews. 1984;8(1):83-93. pubmed.ncbi.nlm.nih.gov/6145137
3. Graf MV, Kastin AJ. Delta-Sleep-Inducing Peptide (DSIP): An Update. Peptides. 1986;7(6):1165-1187. pubmed.ncbi.nlm.nih.gov/3550726
4. Kovalzon VM, Strekalova TV. Delta Sleep-Inducing Peptide (DSIP): A Still Unresolved Riddle. Journal of Neurochemistry. 2006;97(2):303-309. pubmed.ncbi.nlm.nih.gov/16539679
5. Schneider-Helmert D, Graf M, Schoenenberger GA. Synthetic Delta-Sleep-Inducing Peptide Improves Sleep in Insomniacs. The Lancet. 1981;1(8232):1256-1257. pubmed.ncbi.nlm.nih.gov/6112579
6. Schneider-Helmert D. Effects of Delta-Sleep-Inducing Peptide on 24-Hour Sleep-Wake Behaviour in Severe Chronic Insomnia. European Neurology. 1987;27(2):120-129. pubmed.ncbi.nlm.nih.gov/3622582
7. Bes F, Hofman W, Schuur J, Van Boxtel C. Effects of Delta Sleep-Inducing Peptide on Sleep of Chronic Insomniac Patients. A Double-Blind Study. Neuropsychobiology. 1992;26(4):193-197. pubmed.ncbi.nlm.nih.gov/1299794
8. Larbig W, Gerber WD, Kluck M, Schoenenberger GA. Therapeutic Effects of Delta-Sleep-Inducing Peptide (DSIP) in Patients with Chronic, Pronounced Pain Episodes. A Clinical Pilot Study. European Neurology. 1984;23(5):372-385. pubmed.ncbi.nlm.nih.gov/6548970
9. Hösli E, Schoenenberger GA, Hösli L. Autoradiographic Localization of Binding Sites for the Delta Sleep-Inducing Peptide ([3H]DSIP) on Neurons of Cultured Rat Brainstem. Brain Research. 1983;279(1-2):374-376. pubmed.ncbi.nlm.nih.gov/6688964
10. Zlokovic BV, Susic VT, Davson H, et al. Saturable Mechanism for Delta Sleep-Inducing Peptide (DSIP) at the Blood-Brain Barrier of the Vascularly Perfused Guinea Pig Brain. Peptides. 1989;10(2):249-254. pubmed.ncbi.nlm.nih.gov/2547200

All products sold by NovaEvum are for research and laboratory use only. They are not intended for human or animal consumption, diagnosis, treatment, cure, or prevention of any disease.